Endometrial Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Z
Recruiting
  • Gynecologic Cancer
  • +11 more
  • Neoantigen specific TCR-T cell drug product
  • Houston, Texas
    MD Anderson Cancer Center
2022-01-15
Jan 15, 2022
N
Completed
  • Ovarian Cancer
  • +4 more
    • New York, New York
      Columbia University
    2022-01-13
    Jan 13, 2022
    C
    Recruiting
    • Lung Neoplasms
    • +12 more
    • CK-301 (cosibelimab)
    • Wollongong, New South Wales, Australia
    • +47 more
    2022-01-11
    Jan 11, 2022
    N
    Completed
    • Triple Negative Breast Cancer
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2021-12-17
    Dec 17, 2021
    E
    Recruiting
    • Ovarian Cancer
    • +68 more
    • Phoenix, Arizona
    • +5 more
    2022-01-10
    Jan 10, 2022
    M
    Recruiting
    • Endometrial Cancer
    • Carcinosarcoma
    • Basking Ridge, New Jersey
    • +6 more
    2022-01-11
    Jan 11, 2022
    F
    Completed
    • Breast Cancer
    • +3 more
    • FPA150
    • Pembrolizumab
    • Scottsdale, Arizona
    • +17 more
    2022-01-06
    Jan 6, 2022
    N
    Completed
    • Endometrial Cancer
    • Nintedanib or Placebo; Carboplatin, Paclitaxel
    • Copenhagen, Sjaelland, Denmark
      NSGO
    2022-01-07
    Jan 7, 2022
    N
    Completed
    • Endometrial Cancer
    • Copenhagen, Sjaelland, Denmark
      NSGO-CTU
    2022-01-07
    Jan 7, 2022
    N
    Recruiting
    • Cervical Cancer
    • +4 more
    • HDR Brachytherapy
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-01-08
    Jan 8, 2022
    C
    Recruiting
    • HER2-positive
    • +30 more
    • CT-0508
    • Duarte, California
    • +3 more
    2022-01-06
    Jan 6, 2022
    E
    Recruiting
    • Breast Cancer
    • +3 more
    • Gilbert, Arizona
    • +77 more
    2022-01-05
    Jan 5, 2022
    I
    Completed
    • Lung Cancer
    • +10 more
    • Birmingham, Alabama
    • +19 more
    2022-01-04
    Jan 4, 2022
    V
    Recruiting
    • Inherited Cancer Syndrome
    • +4 more
    • Correlative Studies (Survey)
    • +4 more
    • Nashville, Tennessee
      Vanderbilt-Ingram Cancer Center
    2021-12-30
    Dec 30, 2021
    A
    Recruiting
    • Ovarian Cancer
    • +12 more
    • Duarte, California
    • +39 more
    2021-12-23
    Dec 23, 2021
    M
    Active, not recruiting
    • Cervical Cancer
    • Endometrial Cancer
    • 18F-Fluorodeoxyglucose (18F-FDG)
    • +2 more
    • Basking Ridge, New Jersey
    • +6 more
    2021-12-28
    Dec 28, 2021
    F
    Recruiting
    • Endometrial Cancer
    • Sentinel node procedure
    • Selective staging
    • Lexington, Kentucky
      University of Kentucky
    2021-12-27
    Dec 27, 2021
    N
    Recruiting
    • Cervical Cancer
    • +5 more
    • NGS analysis of ctDNA
    • Tokyo, Japan
    • +9 more
    2021-12-27
    Dec 27, 2021
    T
    Not yet recruiting
    • Solid Tumor
    • +11 more
    • (no location specified)
    2021-12-22
    Dec 22, 2021
    B
    Not yet recruiting
    • Solid Tumor, Adult
    • +5 more
    • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
    • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
    • (no location specified)
    2021-12-07
    Dec 7, 2021
    A
    Recruiting
    • Breast Cancer
    • +3 more
    • Duarte, California
    • +7 more
    2021-12-21
    Dec 21, 2021